Reuters logo
BRIEF-Achaogen Inc says strategic milestone achieved in TDM Assay development
February 22, 2017 / 9:15 PM / 7 months ago

BRIEF-Achaogen Inc says strategic milestone achieved in TDM Assay development

Feb 22 (Reuters) - Achaogen Inc

* Achaogen Inc says strategic milestone achieved in TDM Assay development

* Achaogen Inc says Thermo Fisher Scientific to develop and then commercialize its assay for measuring concentration of plazomicin

* Achaogen Inc says achieved a strategic milestone in their ongoing efforts to develop an assay enabling therapeutic drug management of plazomicin

* Plans to submit a new drug application (NDA) for plazomicin to Food and Drug Administration (FDA) in second half of 2017

* Says also plans to submit a marketing authorization application (MAA) to European Medicines Agency (EMA) in 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below